Julie R. Brahmer, MD

Julie Brahmer, MD, MSc, is the co-director of the Upper Aerodigestive Department at the Bloomberg-Kimmel Institute for Cancer Immunotherapy, the co-director of the Cancer Immunotherapy Program, the director of Thoracic Oncology, and the Marilyn Meyerhoff Professor in Thoracic Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Articles by Julie R. Brahmer, MD

Lung Cancer Experts Highlight the Significance and Limitations of ADCs

ByEstelamari Rodriguez, MD, MPH,Tarek M. Mekhail, MD, MSc, FRCSI, FRCSEd,Balazs Halmos, MD, MS ,Susan Scott, MD,Julie R. Brahmer, MD,Corey J. Langer, MD,Benjamin P. Levy, MD

April 30th 2025

Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.

Clinical Pearls and Closing Thoughts on NSCLC Treatment Landscape

ByMartin Dietrich, MD, PhD,Julie R. Brahmer, MD,Antonia Sepulveda, MD, PhD,Joshua K. Sabari, MD,Luis E. Raez, MD

October 10th 2023

Closing out their discussion on biomarker testing and targeted therapies in non–small cell lung cancer, the panel of expert oncologists share clinical pearls and thoughts on the evolving treatment landscape.

Julie R. Brahmer, MD, an expert on lung cancer

Emerging Targets in Non–Small Cell Lung Cancer

ByMartin Dietrich, MD, PhD,Julie R. Brahmer, MD,Antonia Sepulveda, MD, PhD,Joshua K. Sabari, MD,Luis E. Raez, MD

October 10th 2023

Julie R. Brahmer, MD, details emerging targets in non–small cell lung cancer and the outlook for the future of treatment.

Treating MET Exon 14 NSCLC

ByMartin Dietrich, MD, PhD,Julie R. Brahmer, MD,Antonia Sepulveda, MD, PhD,Joshua K. Sabari, MD,Luis E. Raez, MD

October 3rd 2023

The focus turns to therapeutic strategies for treating MET exon 14 non–small cell lung cancer.

Approach to Treating Patients with NSCLC and RET Fusions

ByMartin Dietrich, MD, PhD,Julie R. Brahmer, MD,Antonia Sepulveda, MD, PhD,Joshua K. Sabari, MD,Luis E. Raez, MD

October 3rd 2023

Experts on non–small cell lung cancer share their approaches to treating patients who have RET fusions and review updates on selpercatinib and pralsetinib.

Dr Brahmer on the Investigation of FLX475 in NSCLC

ByJulie R. Brahmer, MD

October 3rd 2023

Julie Renee Brahmer, MD, discusses the investigation of FLX475 in patients with advanced non–small cell lung cancer.

Treatment of NTRK Fusions in NSCLC

ByMartin Dietrich, MD, PhD,Julie R. Brahmer, MD,Antonia Sepulveda, MD, PhD,Joshua K. Sabari, MD,Luis E. Raez, MD

September 26th 2023

Julie R. Brahmer, MD, and Joshua K. Sabari, MD, review recent data on entrectinib and larotrectinib for the treatment of patients with NSCLC with NTRK fusions.

Choosing Between ALK Inhibitors in the Treatment of NSCLC

ByMartin Dietrich, MD, PhD,Julie R. Brahmer, MD,Antonia Sepulveda, MD, PhD,Joshua K. Sabari, MD,Luis E. Raez, MD

September 26th 2023

The expert panel discusses factors that influence treatment decisions when choosing appropriate therapy for patients with ALK-rearranged NSCLC.

Emerging Treatment Options for Patients with NSCLC with ALK Rearrangements

ByMartin Dietrich, MD, PhD,Julie R. Brahmer, MD,Antonia Sepulveda, MD, PhD,Joshua K. Sabari, MD,Luis E. Raez, MD

September 19th 2023

Experts on non–small cell lung cancer discuss recent data on brigatinib and lorlatinib for the treatment of patients with ALK rearrangements.

Is There a Role for Immunotherapy in Patients with KRAS G12C-Mutant NSCLC and STK11 or KEAP1 Co-Mutations?

ByMartin Dietrich, MD, PhD,Julie R. Brahmer, MD,Antonia Sepulveda, MD, PhD,Joshua K. Sabari, MD,Luis E. Raez, MD

September 19th 2023

Luis Raez, MD, offers insights on how co-mutations in STK11 or KEAP1 impact the use of immunotherapies in KRAS G12C–mutant non–small cell lung cancer.

Joshua K. Sabari, MD, an expert on lung cancer

Adagrasib for Patients with KRAS G12C–Mutant NSCLC

ByMartin Dietrich, MD, PhD,Julie R. Brahmer, MD,Antonia Sepulveda, MD, PhD,Joshua K. Sabari, MD,Luis E. Raez, MD

September 12th 2023

Joshua K. Sabari, MD, discusses adagrasib as a treatment of patients with NSCLC with KRAS G12C mutations, and provides insight on treating patients who have progressed on prior KRAS G12C inhibitors.

Sotorasib in the Treatment of KRAS G12C–Mutant NSCLC

ByMartin Dietrich, MD, PhD,Julie R. Brahmer, MD,Antonia Sepulveda, MD, PhD,Joshua K. Sabari, MD,Luis E. Raez, MD

September 12th 2023

Expert panelists review the CodeBreaK trials focused on sotorasib in the treatment of patients with KRAS G12C-mutant non–small cell lung cancer.

NSCLC With Uncommon EGFR Mutations: First-Generation EGFR TKIs and Role of Immunotherapy

ByMartin Dietrich, MD, PhD,Julie R. Brahmer, MD,Antonia Sepulveda, MD, PhD,Joshua K. Sabari, MD,Luis E. Raez, MD

September 5th 2023

Shared insight on the use of first-generation EGFR tyrosine kinase inhibitors and the role of immunotherapy in treating patients with NSCLC with uncommon EGFR mutations.

Choosing Treatments for Patients with NSCLC with Uncommon EGFR Mutations

ByMartin Dietrich, MD, PhD,Julie R. Brahmer, MD,Antonia Sepulveda, MD, PhD,Joshua K. Sabari, MD,Luis E. Raez, MD

September 5th 2023

Julie R. Brahmer, MD, discusses treatment considerations when choosing between afatinib and osimertinib in patients with NSCLC with rare EGFR mutations.

Treatment Options for Patients with NSCLC with EGFR Mutations

ByMartin Dietrich, MD, PhD,Julie R. Brahmer, MD,Antonia Sepulveda, MD, PhD,Joshua K. Sabari, MD,Luis E. Raez, MD

August 29th 2023

Key opinion leaders on non–small cell lung cancer review treatment options for patients with EGFR mutations.

Strategies to Improve Biomarker Testing in NSCLC

ByMartin Dietrich, MD, PhD,Julie R. Brahmer, MD,Antonia Sepulveda, MD, PhD,Joshua K. Sabari, MD,Luis E. Raez, MD

August 29th 2023

Experts on non–small cell lung cancer discuss strategies to improve molecular testing and opportunities for community physicians to reach out to expert oncologists for clinical insights.

Antonia Sepulveda, MD, PhD, an expert on lung cancer

Biomarker Testing Patterns in Academic and Community Settings Treating NSCLC

ByMartin Dietrich, MD, PhD,Julie R. Brahmer, MD,Antonia Sepulveda, MD, PhD,Joshua K. Sabari, MD,Luis E. Raez, MD

August 22nd 2023

Antonia Sepulveda, MD, PhD, an expert on NSCLC, outlines discrepancies in molecular testing between academic and community settings.

Latest Updated Articles

Is There a Role for Immunotherapy in Patients with KRAS G12C-Mutant NSCLC and STK11 or KEAP1 Co-Mutations?
Published: September 19th 2023 | Updated:
Dr. Brahmer on the Examination of Nemvaleukin Alfa in Solid Tumors
Published: July 16th 2022 | Updated:
Emerging Treatment Options for Patients with NSCLC with ALK Rearrangements
Published: September 19th 2023 | Updated:
Adagrasib for Patients with KRAS G12C–Mutant NSCLC
Published: September 12th 2023 | Updated:
Dr. Brahmer on Emerging Targeted Therapies in EGFR Exon 20–Mutated Lung Cancer
Published: February 10th 2021 | Updated:
Dr. Brahmer on Treatment Following Progression on First-line Immunotherapy in NSCLC
Published: March 8th 2023 | Updated:

Julie R. Brahmer, MD

Articles by Julie R. Brahmer, MD

Lung Cancer Experts Highlight the Significance and Limitations of ADCs

Clinical Pearls and Closing Thoughts on NSCLC Treatment Landscape

Emerging Targets in Non–Small Cell Lung Cancer

Treating MET Exon 14 NSCLC

Approach to Treating Patients with NSCLC and RET Fusions

Dr Brahmer on the Investigation of FLX475 in NSCLC

Treatment of NTRK Fusions in NSCLC

Choosing Between ALK Inhibitors in the Treatment of NSCLC

Emerging Treatment Options for Patients with NSCLC with ALK Rearrangements

Is There a Role for Immunotherapy in Patients with KRAS G12C-Mutant NSCLC and STK11 or KEAP1 Co-Mutations?

Adagrasib for Patients with KRAS G12C–Mutant NSCLC

Sotorasib in the Treatment of KRAS G12C–Mutant NSCLC

NSCLC With Uncommon EGFR Mutations: First-Generation EGFR TKIs and Role of Immunotherapy

Choosing Treatments for Patients with NSCLC with Uncommon EGFR Mutations

Treatment Options for Patients with NSCLC with EGFR Mutations

Strategies to Improve Biomarker Testing in NSCLC

Biomarker Testing Patterns in Academic and Community Settings Treating NSCLC

Latest Updated Articles

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma

FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care